Liver-related Solutions & Services
Traditionally, drug hepatotoxicity evaluations rely on animal studies that have limitations such as high costs, long durations, and ethical concerns. However, liver organoids enable an in vitro simulation of drug toxicity effects, providing a rapid and accurate assessment for drug safety. Moreover, liver organoids can mimic the pathogenesis of various liver diseases such as hepatitis, liver cirrhosis, and liver cancer, aiding in early diagnosis and monitoring, as well as exploring treatment options.
Liver Organoids
Liver organoids are a miniaturized, in vitro version of the liver that is derived from induced pluripotent stem cells (iPSCs). These organoids are designed to have a similar cellular composition and architecture to the liver, reflecting human-specific drug metabolism. As such, liver organoids are critical tools for researchers, enabling personalized drug screening and replicating key hepatic functions while mimicking the physiological architecture of the liver.
Drug Screening +
Drug Screening
Liver organoids derived from human cells mimic native liver tissue and have functional properties, enabling their application in a scalable, high-throughput drug screening including efficacy and toxicity assessments.
Liver Development Research +
Liver Development Research
By utilizing liver organoids, researchers can investigate various biological events during liver development, such as cell differentiation, proliferation, migration, and apoptosis. These studies contribute significantly to uncovering the molecular mechanisms.
Personalized Medicine +
Personalized Medicine
Defining a treatment strategy is the foundation of personalized medicine. Personalized medicine utilizing liver organoids has the potential to screen for therapeutic efficacy while minimizing side effects on an individual scale.
Liver organoids and differentiation kits are available to support high-throughput differentiation of liver organoids from iPSCs.
Derived from diverse populations, liver organoids enable personalized drug screening.
Mimicking physiological architecture, liver organoids replicate key hepatic functions.
The Liver Organoids differentiated by using the Human iPSC-Derived Liver Organoid Differentiation Kit expressed hepatic marker (ALB), cholangiocyte marker (CK19) and endothelial marker (CD31).
| Cat. No. | Description |
| CIPO-RWL005K | Ready-to-use Human iPSC-Derived Liver Organoids |
| RIPO-RWM010 | Human iPSC-Derived Liver Organoid Maturation and Maintenance Kit |
Liver Cells
iPSC-differentiated Liver cells are coming soon!
Interested? Leave a message!
Liver Services
Organoid Differentiation and Validation Services
We utilize specific cytokines and stimuli to induce reprogramming or differentiation of iPSC or human tissue. The differentiation and maturation of organoids are identified by the expression of liver-related protein markers.
Validation by WB, IF, qPCR for CK19, ALB
Raw data and images
Detailed validation test report
Hepatotoxicity Assessment
We measure the inhibition of CYP450 expression and enzyme activity under the action of the drug, since the ALB secreted into the medium also represents the liver activity.
Enzyme activity test: CYP450s family’s activity
Liver injury detection by ALT test
Raw data and images
Metabolic Dysfunction-associated Steatohepatitis (MASH)
We can help to construct the MASH model and provide corresponding pathological and biochemical evidence. At the same time, we can also provide you with follow-up MASH related drug screening services.
Validation：WB, IF, qPCR for the organoid validation by CK19, ALB.
Pathological examination by oil red O stain for fat accumulation test
Validation of inflammatory factors
Detailed validation test report
Custom MASH model based on organoid
Liver Case Studies
Modeling MASH with Liver Organoids
MASH, a chronic liver disease characterized by fat accumulation, inflammation, and liver damage, is closely associated with obesity, type 2 diabetes, and metabolic syndrome. Oil Red is a dye used to detect intracellular lipid deposition, effectively visualizing fatty acid accumulation in liver organoids.
qPCR analysis showed markedly increased expression of inflammatory markers such as IL-6 and IL-33, further confirming the successful modeling of key inflammatory characteristics of MASH in the liver organoids.
Assessment of Drug-Induced Hepatotoxicity (Based on Cell Viability Assay)
Troglitazone, known for its severe hepatotoxicity, is often used as a compound to induce liver injury in vitro. AO/PI staining is a common fluorescence method for assessing cell viability and death, allowing rapid distinction between live (green) and dead cells (red), making it useful for evaluating drug-induced cytotoxicity.
Assessment of Drug-Induced Oxidative Stress with Liver Organoids
The hepatotoxic positive control drug acetaminophen (APAP) was applied to liver organoids, and intracellular ROS accumulation was detected using a reactive oxygen species (ROS)-specific fluorescent probe to assess drug-induced oxidative stress.
Related Recommendations
References
1. Kulkeaw, K.; Pengsart, W. Progress and Challenges in the Use of a Liver-on-a-Chip for Hepatotropic Infectious Diseases. Micromachi nes 2021, 12, 842. https://doi.org/10.33 90/mi12070842.
2. akebe, T., Sekine, K., Enomura, M. et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 499, 481–484 (2013).
- Background
- Liver Organoids
- Liver Cells
- Liver Services
- Liver Case Studies
- Related Recommendations
- References